EXECUTIVE SUMMARY

SIRPant Immunotherapeutics Inc., founded in May 2020, is a privately held emerging biotechnology company focused on the development of novel autologous cell therapy for solid tumors. The company believes its proprietary technologies for empowering patient innate and adaptive immune responses against cancer will play a leading role in the successful treatment of solid tumors. The company is initially focusing on solid tumors of unmet need including colon, lung, lymphoma, and pancreatic cancer.

Technology

Macrophages are pivotal in the decision to either eliminate or tolerate cancer cells. Productive cancerous masses evade macrophage activity in part by engaging inhibitory receptor SIRPα, thereby suppressing macrophage phagocytic activity and cancer elimination. Additionally, SIRPα inhibits consequent anti-tumor adaptive immune responses, leading to impairment of cancer-specific T cell responses.

SIRPant technology comprises an innovative approach to engineer SIRPα\textsuperscript{low} macrophages for robust phagocytosis and for initiation of tumor-specific immune responses. Cells from a simple blood draw, are manipulated \textit{in vitro}, and are delivered to the tumor via direct injection or IV infusion. SIRPant’s proprietary macrophage modification overcomes resistance to the effects of immunosuppressive cytokines and reprograms the tumor microenvironment toward a pro-inflammatory state. This results in digestion of the tumor and initiation of tumor specific adaptive immune responses. This cellular therapy approach was chosen based on studies that demonstrated that this response cannot be recapitulated or even approximated using anti-SIRPα antibodies.

Market Need

While immunotherapies have revolutionized solid tumor treatment, their efficacy has continued to be a point of concern as only a limited number of patients benefit. For example, 15-25% of patients treated with immune checkpoint inhibitors show a response, with the remaining 75-85% of patients seeing no benefit. The lack of efficacy in current immunotherapies has been associated with a “cold” tumor microenvironment in which anticancer T cells are scarce and functionally suppressed. The specific cancer types, stage of progression, genetics, and treatment history also play a role. SIRPant technology addresses one of the major challenges in advancing immunotherapy: developing agents that consistently elicit anti-tumor immunity in a broad set of patients and cancer types.

Status

\textit{In vivo} proof of principle has been completed for the technology in mouse cancer models and complemented by \textit{ex vivo} human studies. Results show that SIRPant technology enables rapid tumor elimination and potent induction of anticancer T cells and B cells with concomitant prevention of tumor recurrence.

Next Steps

Immediate next steps include closing a seed financing of $500,000 - $5M in 2020; completing Pre-IND testing for SIRPα\textsuperscript{low} macrophages; filing of an IND; and initiating a Phase 1 clinical trial in 2021.
Proprietary technology platform potently empowering the immune system in a controlled and targeted manner.

- SIRPant is Adoptive Cell Therapy (ACT) -
  - Tumor-specific T-cells induced through one of two alternative means
    - *In vivo* through proprietary activated macrophages
      - Activates tumoricidal Macrophages, Neutrophils, T Cells & Natural Killer Cells
      - Curtails Tregs, MDSCs, IL-10 & TGFβ
    - *Ex vivo* through expansion of tumor-infiltrating T lymphocytes (TIL)
      - Resulting in polyclonal immune response against multiple tumor antigens
      - Broad applicability to unmet need for solid tumors
  - SIRPant thus act as a Cancer Vaccine -
    - *In situ* tumor vaccination for presentation of cancer-associated antigens to immune system
    - Induces T cell & B cell long-lasting immunity
  - Synergistic with Radiation Therapy
    - Complete response and abscopal effects
  - Synergistic with Immune Checkpoint Blockade
    - Complete response in PD-1/L1-refractory pancreatic and colorectal cancers

**Intellectual Property**

SIRPant Immunotherapeutics Inc. has secured an option to the Georgia State University patent portfolio and will execute the full license on closing a Series A financing of $3-$5 M USD.

**Organization**

SIRPant Immunotherapeutics Inc. is initially operating in a virtual environment. The company is a Delaware C Corp in anticipation of raising significant venture capital and eventually an IPO. Corporate Management is currently headquartered in the Philadelphia, PA area while key scientific and medical personnel are located and working in Atlanta, GA.

**Management**

Robert J. Towarnicki Sr., President & Chief Executive Officer

Richard Fitzgerald, Executive VP Finance & Administration

Dennis Kim, MD, Executive VP, Clinical & Regulatory and CMO

Ivy League Immunology PhD, VP R&D (pending Series A)

**Scientific and Medical Advisors**

Yuan Liu, MD, PhD, Founder, Inventor, Technical Lead

Ned Waller, MD, PhD, Clinical Oncology Lead, Emory Medical School

Mohammed Khan, MD, Radiation Oncology Lead, Emory Medical School

Rifat Pamukcu, MD, Biotech Entrepreneur
DISCLAIMERS

This presentation contains a non-confidential summary of SIRPant Immunotherapeutics, Inc. and matters relating to its business and does not contain all of the information that a person may require to make an investment decision regarding the purchase or sale of the Company’s securities. For additional information, please contact Robert J. Towarnicki, the President of SIRPant Immunotherapeutics, at rjtowarnicki@outlook.com.

Certain statements set forth in this presentation or made by management that are not historical facts are “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements involve risks and uncertainties because they relate to events or circumstances that may or may not occur in the future, and, therefore, actual future events may differ materially from these statements.

An investment in SIRPant Immunotherapeutics involves a high degree of risk that is suitable only for persons of substantial means who have no need for liquidity in their investment and who can afford to lose their entire investment. Investors in SIRPant Immunotherapeutics must be “accredited investors” as defined in Regulation D under the Securities Act of 1933, as amended.

The statements set forth in this presentation are made as of the date hereof. SIRPant Immunotherapeutics does not undertake any obligation to update this presentation, whether as a result of new information, future events or otherwise.